Trade Merck KGaA - EUR - MRKd CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.65 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.024161% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | -0.020283% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | EUR | ||||||||
Margin | 20% | ||||||||
Stock exchange | Germany | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Merck KGaA ESG Risk Ratings
‘A’ score indicates excellent relative ESG performance and high degree of transparency in reporting material ESG data publicly
Prev. Close* | 185.8 |
Open* | 184.9 |
1-Year Change* | -3.14% |
Day's Range* | 184.35 - 186.45 |
52 wk Range | 153.10-202.80 |
Average Volume (10 days) | 291.04K |
Average Volume (3 months) | 6.14M |
Market Cap | 24.03B |
P/E Ratio | 23.29 |
Shares Outstanding | 434.78M |
Revenue | 21.79B |
EPS | 7.98 |
Dividend (Yield %) | 0.99516 |
Beta | 0.57 |
Next Earnings Date | Mar 2, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Feb 3, 2023 | 185.80 | 3.60 | 1.98% | 182.20 | 186.25 | 181.00 |
Feb 2, 2023 | 183.70 | 4.20 | 2.34% | 179.50 | 184.80 | 179.45 |
Feb 1, 2023 | 181.80 | -7.00 | -3.71% | 188.80 | 188.85 | 181.10 |
Jan 31, 2023 | 190.75 | -2.60 | -1.34% | 193.35 | 193.55 | 189.65 |
Jan 30, 2023 | 193.60 | 4.10 | 2.16% | 189.50 | 194.05 | 188.95 |
Jan 27, 2023 | 190.05 | -1.40 | -0.73% | 191.45 | 191.90 | 189.55 |
Jan 26, 2023 | 192.30 | -1.90 | -0.98% | 194.20 | 195.45 | 192.30 |
Jan 25, 2023 | 190.45 | 1.65 | 0.87% | 188.80 | 191.00 | 187.15 |
Jan 24, 2023 | 189.45 | -2.55 | -1.33% | 192.00 | 192.75 | 188.80 |
Jan 23, 2023 | 192.55 | 3.30 | 1.74% | 189.25 | 193.05 | 188.45 |
Jan 20, 2023 | 186.55 | -1.80 | -0.96% | 188.35 | 191.20 | 186.50 |
Jan 19, 2023 | 189.35 | -1.50 | -0.79% | 190.85 | 191.00 | 186.80 |
Jan 18, 2023 | 192.35 | -3.95 | -2.01% | 196.30 | 196.40 | 192.15 |
Jan 17, 2023 | 196.00 | -2.70 | -1.36% | 198.70 | 198.75 | 195.40 |
Jan 16, 2023 | 199.20 | 1.15 | 0.58% | 198.05 | 200.00 | 197.85 |
Jan 13, 2023 | 197.65 | 2.45 | 1.26% | 195.20 | 197.75 | 193.15 |
Jan 12, 2023 | 196.75 | -3.15 | -1.58% | 199.90 | 200.30 | 192.85 |
Jan 11, 2023 | 200.70 | 6.95 | 3.59% | 193.75 | 202.20 | 193.55 |
Jan 10, 2023 | 192.00 | 2.40 | 1.27% | 189.60 | 192.60 | 189.00 |
Jan 9, 2023 | 193.55 | 5.00 | 2.65% | 188.55 | 193.60 | 187.40 |
Merck KGaA - EUR Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- Annual
- Quarterly
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Total revenue | 15024 | 14517 | 14836 | 16152 | 17534 | 19687 |
Revenue | 15024 | 14517 | 14836 | 16152 | 17534 | 19687 |
Cost of Revenue, Total | 5201 | 5071 | 5342 | 5951 | 6782 | 7325 |
Gross Profit | 9823 | 9446 | 9494 | 10201 | 10752 | 12362 |
Total Operating Expense | 12543 | 12094 | 13109 | 14032 | 14549 | 15508 |
Selling/General/Admin. Expenses, Total | 4409 | 4234 | 4256 | 4686 | 4600 | 4855 |
Research & Development | 1972 | 2102 | 2220 | 2239 | 2262 | 2400 |
Depreciation / Amortization | 1036 | 1020 | 979 | 923 | 636 | 589 |
Interest Expense (Income) - Net Operating | 57 | 3 | 62 | 1 | ||
Unusual Expense (Income) | -46 | -26 | 339 | 389 | 85 | 184 |
Other Operating Expenses, Total | -86 | -310 | -89 | -156 | 184 | 154 |
Operating Income | 2481 | 2423 | 1727 | 2120 | 2985 | 4179 |
Interest Income (Expense), Net Non-Operating | -274 | -243 | -209 | -338 | -350 | -255 |
Other, Net | -53 | -51 | -57 | -47 | -5 | 0 |
Net Income Before Taxes | 2154 | 2129 | 1461 | 1735 | 2630 | 3924 |
Net Income After Taxes | 1633 | 2557 | 1093 | 1295 | 1993 | 3065 |
Minority Interest | -4 | -10 | -22 | -3 | -7 | -10 |
Net Income Before Extra. Items | 1629 | 2547 | 1071 | 1292 | 1986 | 3055 |
Total Extraordinary Items | 0 | 57 | 2303 | 28 | 0 | |
Net Income | 1629 | 2604 | 3374 | 1320 | 1986 | 3055 |
Income Available to Common Excl. Extra. Items | 1629 | 2548 | 1071 | 1292 | 1987 | 3055 |
Income Available to Common Incl. Extra. Items | 1629 | 2605 | 3374 | 1320 | 1987 | 3055 |
Diluted Net Income | 1629 | 2605 | 3374 | 1320 | 1987 | 3055 |
Diluted Weighted Average Shares | 434.778 | 434.778 | 434.794 | 434.211 | 434.792 | 434.566 |
Diluted EPS Excluding Extraordinary Items | 3.74674 | 5.86046 | 2.46324 | 2.97552 | 4.57 | 7.03 |
Dividends per Share - Common Stock Primary Issue | 1.2 | 1.25 | 1.25 | 1.3 | 1.4 | 1.85 |
Diluted Normalized EPS | 3.66653 | 5.91727 | 3.04653 | 3.6442 | 4.71815 | 7.36072 |
Total Adjustments to Net Income | 1 | 0 | 1 |
Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
---|---|---|---|---|---|
Total revenue | 4631 | 4870 | 4973 | 5213 | 5198 |
Revenue | 4631 | 4870 | 4973 | 5213 | 5198 |
Cost of Revenue, Total | 1721 | 1813 | 1859 | 1959 | 1987 |
Gross Profit | 2910 | 3057 | 3114 | 3254 | 3211 |
Total Operating Expense | 3588 | 3821 | 3926 | 4174 | 4025 |
Selling/General/Admin. Expenses, Total | 1280 | 1342 | 1376 | 1546 | 1374 |
Research & Development | 574 | 585 | 660 | 590 | 586 |
Unusual Expense (Income) | 6 | 0 | -1 | -6 | 5 |
Other Operating Expenses, Total | 7 | 81 | 32 | 85 | 73 |
Operating Income | 1043 | 1049 | 1047 | 1039 | 1173 |
Interest Income (Expense), Net Non-Operating | -60 | -95 | -54 | -47 | -34 |
Other, Net | 1 | 1 | |||
Net Income Before Taxes | 984 | 955 | 993 | 992 | 1139 |
Net Income After Taxes | 748 | 747 | 764 | 806 | 884 |
Minority Interest | -1 | -2 | -3 | -4 | -3 |
Net Income Before Extra. Items | 747 | 745 | 761 | 802 | 881 |
Net Income | 747 | 745 | 761 | 802 | 881 |
Income Available to Common Excl. Extra. Items | 747 | 745 | 761 | 802 | 880 |
Income Available to Common Incl. Extra. Items | 747 | 745 | 761 | 802 | 880 |
Diluted Net Income | 747 | 745 | 761 | 802 | 880 |
Diluted Weighted Average Shares | 434.302 | 434.778 | 434.857 | 433.438 | 435.644 |
Diluted EPS Excluding Extraordinary Items | 1.72 | 1.71352 | 1.75 | 1.85032 | 2.02 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 1.85 | 0 |
Diluted Normalized EPS | 1.80927 | 1.90422 | 1.8827 | 1.80908 | 2.07345 |
Total Adjustments to Net Income | 0 | -1 |
- Annual
- Quarterly
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Total Current Assets | 7670 | 7455 | 9236 | 9003 | 9280 | 10982 |
Cash and Short Term Investments | 981 | 623 | 2199 | 598 | 1234 | 1685 |
Cash & Equivalents | 662 | 481 | 779 | 541 | 1109 | 1511 |
Short Term Investments | 319 | 142 | 1420 | 57 | 125 | 174 |
Total Receivables, Net | 3607 | 3707 | 3738 | 4233 | 3910 | 4345 |
Accounts Receivable - Trade, Net | 2888 | 2923 | 3278 | 3644 | 3390 | 3853 |
Total Inventory | 2609 | 2632 | 2764 | 3342 | 3294 | 3900 |
Prepaid Expenses | 276 | 338 | 435 | 493 | 519 | 570 |
Other Current Assets, Total | 197 | 155 | 100 | 337 | 323 | 482 |
Total Assets | 38258 | 35621 | 36888 | 43811 | 41796 | 45362 |
Property/Plant/Equipment, Total - Net | 4231 | 4512 | 4811 | 6213 | 6421 | 7217 |
Property/Plant/Equipment, Total - Gross | 9404 | 9853 | 10551 | 12561 | 13228 | 14810 |
Accumulated Depreciation, Total | -5172 | -5340 | -5740 | -6348 | -6808 | -7593 |
Goodwill, Net | 15015 | 13582 | 13764 | 17141 | 15959 | 17004 |
Intangibles, Net | 9980 | 8317 | 7237 | 9175 | 7653 | 7612 |
Long Term Investments | 191 | 419 | 1 | 3 | ||
Note Receivable - Long Term | 15 | 41 | 614 | 746 | 830 | 922 |
Other Long Term Assets, Total | 1156 | 1295 | 1226 | 1533 | 1652 | 1622 |
Total Current Liabilities | 9089 | 8635 | 8517 | 11842 | 9231 | 10432 |
Accounts Payable | 2048 | 2195 | 1766 | 2054 | 1768 | 2380 |
Accrued Expenses | 603 | 778 | 799 | 791 | 975 | 1204 |
Notes Payable/Short Term Debt | 1855 | 1173 | 982 | 2224 | 515 | 1434 |
Current Port. of LT Debt/Capital Leases | 1908 | 1590 | 1217 | 2307 | 1780 | 1062 |
Other Current Liabilities, Total | 2675 | 2899 | 3753 | 4466 | 4193 | 4352 |
Total Liabilities | 24269 | 21618 | 19688 | 25945 | 24850 | 24024 |
Total Long Term Debt | 8706 | 7947 | 6608 | 8588 | 9745 | 8270 |
Long Term Debt | 8706 | 7947 | 6608 | 8130 | 9418 | 7928 |
Deferred Income Tax | 2724 | 1489 | 1288 | 1828 | 1441 | 1411 |
Minority Interest | 61 | 63 | 33 | 48 | 71 | 78 |
Other Liabilities, Total | 3689 | 3484 | 3242 | 3639 | 4362 | 3833 |
Total Equity | 13989 | 14003 | 17200 | 17866 | 16946 | 21338 |
Preferred Stock - Non Redeemable, Net | 397 | 397 | 397 | 397 | 397 | 397 |
Common Stock | 168 | 168 | 168 | 168 | 168 | 168 |
Additional Paid-In Capital | 3814 | 3814 | 3814 | 3814 | 3814 | 3814 |
Retained Earnings (Accumulated Deficit) | 8049 | 9902 | 12532 | 13236 | 14556 | 16673 |
Other Equity, Total | 1561 | -278 | 289 | 251 | -1989 | 286 |
Total Liabilities & Shareholders’ Equity | 38258 | 35621 | 36888 | 43811 | 41796 | 45362 |
Total Common Shares Outstanding | 434.778 | 434.778 | 434.778 | 434.778 | 434.778 | 434.778 |
Capital Lease Obligations | 458 | 327 | 342 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Total Current Assets | 10617 | 10182 | 10315 | 10982 | 11085 |
Cash and Short Term Investments | 2298 | 1870 | 1665 | 2073 | 1445 |
Cash & Equivalents | 2238 | 1825 | 1523 | 1899 | 1339 |
Short Term Investments | 60 | 45 | 142 | 174 | 106 |
Total Receivables, Net | 4226 | 4124 | 4207 | 4345 | 4705 |
Accounts Receivable - Trade, Net | 3816 | 3771 | 3930 | 3853 | 4345 |
Total Inventory | 3462 | 3564 | 3760 | 3900 | 4143 |
Other Current Assets, Total | 631 | 624 | 683 | 664 | 792 |
Total Assets | 43891 | 43145 | 43836 | 45362 | 46235 |
Property/Plant/Equipment, Total - Net | 6552 | 6601 | 6761 | 7217 | 7303 |
Goodwill, Net | 16541 | 16347 | 16670 | 17004 | 17761 |
Intangibles, Net | 7765 | 7613 | 7628 | 7612 | 7549 |
Long Term Investments | 770 | 744 | 794 | 914 | 905 |
Note Receivable - Long Term | 38 | 39 | 39 | 35 | 35 |
Other Long Term Assets, Total | 1608 | 1619 | 1629 | 1598 | 1597 |
Total Current Liabilities | 10652 | 9820 | 9793 | 10432 | 10207 |
Accounts Payable | 1937 | 2107 | 2132 | 2380 | 2356 |
Accrued Expenses | 118 | 144 | 191 | 224 | 174 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 3347 | 3278 | 2770 | 2531 | 2345 |
Other Current Liabilities, Total | 5250 | 4291 | 4700 | 5297 | 5332 |
Total Liabilities | 24975 | 23852 | 23229 | 24024 | 23316 |
Total Long Term Debt | 9001 | 8721 | 8195 | 8270 | 8286 |
Long Term Debt | 9001 | 8721 | 8195 | 8270 | 8286 |
Deferred Income Tax | 1440 | 1401 | 1374 | 1411 | 1389 |
Minority Interest | 67 | 68 | 72 | 78 | 71 |
Other Liabilities, Total | 3815 | 3842 | 3795 | 3833 | 3363 |
Total Equity | 18916 | 19293 | 20607 | 21338 | 22919 |
Preferred Stock - Non Redeemable, Net | 397 | 397 | 397 | 397 | |
Common Stock | 168 | 168 | 168 | 168 | 565 |
Additional Paid-In Capital | 3814 | 3814 | 3814 | 3814 | 3814 |
Retained Earnings (Accumulated Deficit) | 15240 | 15799 | 16556 | 16673 | 18540 |
Other Equity, Total | -703 | -885 | -328 | 286 | |
Total Liabilities & Shareholders’ Equity | 43891 | 43145 | 43836 | 45362 | 46235 |
Total Common Shares Outstanding | 434.778 | 434.778 | 434.778 | 434.778 | 434.778 |
- Annual
- Quarterly
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Net income/Starting Line | 1633 | 2615 | 3396 | 1324 | 1994 | 3065 |
Cash From Operating Activities | 2510 | 2696 | 2219 | 2856 | 3477 | 4616 |
Cash From Operating Activities | 1934 | 1758 | 1812 | 1944 | 1938 | 1762 |
Non-Cash Items | -488 | -250 | -2523 | 149 | -59 | 62 |
Changes in Working Capital | -569 | -1427 | -466 | -561 | -396 | -273 |
Cash From Investing Activities | -503 | -1147 | 2191 | -6153 | -1340 | -1578 |
Capital Expenditures | -848 | -1311 | -1016 | -1021 | -1563 | -1421 |
Other Investing Cash Flow Items, Total | 345 | 164 | 3207 | -5132 | 223 | -157 |
Cash From Financing Activities | -1908 | -1870 | -2825 | 1902 | -1522 | -2504 |
Financing Cash Flow Items | -464 | -469 | -607 | -527 | -519 | -576 |
Total Cash Dividends Paid | -136 | -155 | -162 | -162 | -168 | -181 |
Issuance (Retirement) of Debt, Net | -1308 | -1246 | -2056 | 2591 | -835 | -1747 |
Foreign Exchange Effects | 8 | -30 | -5 | 5 | -40 | 9 |
Net Change in Cash | 107 | -351 | 1580 | -1390 | 575 | 543 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | 748 | 1495 | 2258 | 3065 | 884 |
Cash From Operating Activities | 1216 | 2104 | 3571 | 4616 | 840 |
Cash From Operating Activities | 424 | 843 | 1287 | 1762 | 430 |
Non-Cash Items | 6 | 25 | 46 | 62 | -24 |
Changes in Working Capital | 38 | -259 | -20 | -273 | -450 |
Cash From Investing Activities | -346 | -587 | -1226 | -1578 | -1089 |
Capital Expenditures | -362 | -638 | -1155 | -1421 | -498 |
Other Investing Cash Flow Items, Total | 16 | 51 | -71 | -157 | -591 |
Cash From Financing Activities | 6 | -1054 | -2184 | -2504 | -315 |
Financing Cash Flow Items | -55 | -575 | -575 | -576 | -100 |
Total Cash Dividends Paid | 0 | -181 | -181 | -181 | 0 |
Issuance (Retirement) of Debt, Net | 61 | -298 | -1428 | -1747 | -215 |
Foreign Exchange Effects | 7 | 6 | 7 | 9 | 4 |
Net Change in Cash | 883 | 469 | 168 | 543 | -560 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 6.8422 | 8842949 | 0 | 2022-09-27 | LOW |
MFS Investment Management | Investment Advisor/Hedge Fund | 4.84 | 6255325 | 3997581 | 2022-09-27 | LOW |
Fidelity International | Investment Advisor | 3.0193 | 3902150 | 2587266 | 2022-09-19 | LOW |
Fidelity Management & Research Company LLC | Investment Advisor | 2.9271 | 3783100 | -924069 | 2022-05-18 | LOW |
Amundi Asset Management, SAS | Investment Advisor/Hedge Fund | 2.8682 | 3706864 | -407104 | 2022-12-14 | HIGH |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.8079 | 3629024 | 3672 | 2022-12-31 | LOW |
Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 2.3464 | 3032598 | 488031 | 2022-12-31 | LOW |
DWS Investment GmbH | Investment Advisor/Hedge Fund | 1.9124 | 2471640 | 83238 | 2022-12-31 | LOW |
FMR Investment Management (U.K.) Limited | Investment Advisor | 1.3005 | 1680776 | -5936 | 2022-12-31 | LOW |
Deka Investment GmbH | Investment Advisor/Hedge Fund | 1.1334 | 1464775 | -25955 | 2022-12-31 | LOW |
BlackRock Advisors (UK) Limited | Investment Advisor/Hedge Fund | 1.1038 | 1426513 | 15622 | 2022-12-31 | LOW |
Allianz Global Investors GmbH | Investment Advisor | 1.0531 | 1361000 | -28942 | 2022-11-30 | LOW |
Union Investment Privatfonds GmbH | Investment Advisor | 0.9614 | 1242564 | 560959 | 2022-09-30 | LOW |
Eleva Capital SAS | Investment Advisor | 0.8919 | 1152665 | 25800 | 2022-10-31 | HIGH |
MFS International Singapore Pte. Ltd | Investment Advisor | 0.8661 | 1119411 | -22611 | 2022-12-31 | LOW |
BNP Paribas Asset Management France SAS | Investment Advisor/Hedge Fund | 0.8255 | 1066840 | -1655 | 2022-12-31 | LOW |
Lazard Asset Management, L.L.C. | Investment Advisor/Hedge Fund | 0.7985 | 1031971 | -21628 | 2022-12-31 | LOW |
Walter Scott & Partners Ltd. | Investment Advisor/Hedge Fund | 0.7721 | 997924 | -204 | 2022-12-31 | LOW |
J O Hambro Capital Management Limited | Investment Advisor/Hedge Fund | 0.7686 | 993311 | -119431 | 2022-09-30 | MED |
California Public Employees' Retirement System | Pension Fund | 0.7543 | 974843 | -146711 | 2021-06-30 | LOW |
Why choose Capital.com? Our numbers speak for themselves.
Capital.com GroupTraders
Active clients monthly
Monthly investing volume
Withdrawn each month
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Merck - EUR Company profile
About Merck KGaA
Merck KGaA is a Germany-based science and technology company. The Company operates in three business segments: Healthcare, Life Sciences and Electronics. The Healthcare business, which operates in the United States and Canada as EMD Serono, focuses on such therapeutic areas as allergies, fertility, oncology and neurodegenerative diseases, developing drugs, diagnostic substances and medical devices. The Life Sciences business comprises the activities of MilliporeSigma, which provides solutions that facilitate biotechnology and pharmaceutical research. The product range includes laboratory water systems, gene editing tools, cell lines and end-to-end drug manufacturing systems, among others. The Electronics business enables digital living and provides specialty chemicals for various applications, including liquid crystals for electronic displays, materials for integrated circuits, effect pigments for coatings and color cosmetics, as well as functional materials for energy solutions.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Merck KGaA revenues increased 12% to EUR19.69B. Net income applicable to common stockholders increased 54% to EUR3.06B. Revenues reflect Life Science segment increase of 20% to EUR8.99B, Healthcare segment increase of 7% to EUR7.09B, United States (Country) segment increase of 13% to EUR5.25B, Rest of Europe segment increase of 14% to EUR4.03B.
Equity composition
2003 Q1 has been restated to reflect discontinued operations. 01/2007, Rights Issue, 4 new shares for every 29 shares held @ EUR 78 (Factor: 1.015602). 6/2014, 2-for-1 stock split (Factor: 2).
Industry: | Proprietary & Advanced Pharmaceuticals |
Frankfurter Str. 250
DARMSTADT
HESSEN 64293
DE
Income Statement
- Annual
- Quarterly
News

Japanese Yen Outlook: USD/JPY Edging Towards YTD Peak on BoJ Dove and US Yields
Japanese Yen underperforms with BoJ dove touted to be Governor Kuroda successor.
14:36, 6 February 2023
S&P 500 & DAX 40 Forecast for the Week Ahead
S&P 500 builds higher after Fed meeting, DAX 40 runs into resistance
16:30, 3 February 2023
FX Weekly Outlook: USD, GBP/USD, USD/JPY Analysis
USD, GBP/USD, USD/JPY forecasts for the week ahead.
15:56, 3 February 2023
GBP/USD drops below 1.23 as BOE comments suggest possible end of rate hikes
Despite increasing rates by 50bps at their February meeting, the messaging from the BOE suggests a dovish tilt an the possible end of rate hikes.
15:37, 2 February 2023
Gold latest: XAU/USD rallies on Fed meeting as traders eye Friday’s jobs data
Gold buyers take advantage of risk on sentiment as they eye Friday's NFP data to assess the likelihood of a soft landing
11:48, 2 February 2023People also watch
Still looking for a broker you can trust?
Join the 480.000+ traders worldwide that chose to trade with Capital.com